Short Interest in Curanex Pharmaceuticals Inc (NASDAQ:CURX) Increases By 96.7%

Curanex Pharmaceuticals Inc (NASDAQ:CURX) was the target of a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 24,375 shares, a growth of 96.7% from the July 30th total of 12,389 shares. Approximately 2.6% of the shares of the company are sold short. Based on an average daily volume of 152,801 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC purchased a new stake in Curanex Pharmaceuticals Inc (NASDAQ:CURX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 64,067 shares of the company’s stock, valued at approximately $46,000.

Curanex Pharmaceuticals Stock Down 2.6%

Shares of NASDAQ CURX opened at $4.56 on Friday. Curanex Pharmaceuticals has a 52-week low of $3.58 and a 52-week high of $183.59. The company’s 50-day simple moving average is $4.49 and its 200-day simple moving average is $6.54. The firm has a market cap of $7.16 million and a price-to-earnings ratio of -0.58.

Curanex Pharmaceuticals (NASDAQ:CURX) last posted its quarterly earnings data on Friday, August 14th. The company reported ($2.40) EPS for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a report on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Curanex Pharmaceuticals currently has an average rating of “Sell”.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.